DEVELOPMENT OF A NEW MOLECULAR TARGETING THERAPY FOR ESOPHAGEAL CANCER USING CYCLIN DEPENDENT KINASE (CDK) INHIBITOR
DEVELOPMENT OF A NEW MOLECULAR TARGETING THERAPY FOR ESOPHAGEAL CANCER USING CYCLIN DEPENDENT KINASE (CDK) INHIBITOR
批准号:
14571228
负责人:
KAJIYAMA Yoshiaki
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Purpose: Flavopiridol is a synthetic flavone that has shown an antitumor effect against several cancers. Here, we investigated the in vitro effect of flavopiridol alone and the combined effect of low-dose flavopiridol plus radiation on esophageal squamous cell carcinoma cell lines. Experimental design: Esophageal squamous cell carcinoma cell lines (TE8, TE9, and KE4) were exposed to flavopiridol (0.05-400 nM) for 48 h. Cytotoxicity was evaluated by the MTT assay, cell cycle distribution was determined by flow cytometry, and cyclin Dl, Bcl-2, and Rb protein expression was detected by Western blotting. The effect of 0.05 nM flavopiridol combined with radiation was determined by the clonogenic assay. Results: The IC_<50> was approximately 110-250 nM. Exposure to 0.05 nM flavopiridol for 48 h increased the G_2 /M population, while 300 nM increased the G_1 population. At a concentration of 300 nM, nuclear fragmentation and chromatin condensation were observed in all three cell lines. Exposure to 300 nM flavopiridol decreased the levels of cyclin Dl and Rb protein in all three cell lines and bcl-2 protein was also decreased in TE8 and KE4 cells. Moreover, exposure to 0.05 nM flavopiridol slightly decreased the levels of cyclin D1, Rb, and Bcl-2 protein in KE4 cells. A significant synergistic effect of 0.05 nM flavopiridol and radiation was observed for all three cell lines. Conclusion: Combined treatment with low-dose flavopiridol and radiation showed a synergistic effect on esophageal squamous cell carcinoma. Administration of a low dose of flavopiridol could be a potent new therapeutic approach for improving the efficacy of radiotherapy against esophageal cancer.
期刊论文(44)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
梶山美明: "食道癌の治療2)右開胸手術"日外会誌. 103(4). 343-347 (2002)
Yoshiaki Kajiyama:“食道癌的治疗2)右侧胸廓切开术”日本盖亚协会杂志103(4)343-347(2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
梶山美明: "Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus : multivariate analysis of predictive factors and p53 overexpression"Dis Esophagus. 15(1). 61-66 (2002)
Yoshiaki Kajiyama:“晚期食管鳞状细胞癌新辅助治疗的组织病理学效应:预测因素和 p53 过度表达的多变量分析”Dis Esophagus 15(1)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hattori K 他: "Mutation of the p53 gene predicts lymph node metastases in Japanese patients with esophageal carcinoma : DNA and immunohistochemical analysis."Dis Esophagus. 16. 301-306 (2003)
Hattori K 等人:“p53 基因突变可预测日本食管癌患者的淋巴结转移:DNA 和免疫组织化学分析。”Dis Esophagus,16. 301-306 (2003)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
梶山美明 他: "食道癌治療のControversy-外科の立場から-"癌と化学療法. 30(9). 1225-1229 (2003)
Yoshiaki Kajiyama 等人:“从手术角度看食管癌治疗的争议”《癌症与化疗》30(9) (2003)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kajiyama Y et al.: "Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus: multivatiate analysis of predicive factors and p53 overexpression."Dis Esophagus. 15. 61-66 (2002)
Kajiyama Y 等人:“新辅助疗法对晚期食管鳞状细胞癌的组织病理学影响:预测因素和 p53 过度表达的多因素分析。”Dis Esophagus。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 17 条
Histopathologic Effects of Neoadjuvant Therapy for Esophageal Cancer and p53 status
-
批准号:11671296
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:1999
-
负责人:KAJIYAMA Yoshiaki
-
依托单位:
p53 gene mutation in Japanese patients with esophageal
-
批准号:09671353
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:1997
-
负责人:KAJIYAMA Yoshiaki
-
依托单位:
国内基金
海外基金
Flavopiridol联合靶向调控的活性caspase-3基因治疗人卵巢癌的实验研究
-
批准号:30471818
-
项目类别:面上项目
-
资助金额:21.0万元
-
批准年份:2004
-
负责人:沈铿
-
依托单位:
Cdk4在Niemann-Pick病C型小鼠模型神经元变性中的作用
-
批准号:30270484
-
项目类别:面上项目
-
资助金额:19.0万元
-
批准年份:2002
-
负责人:卜碧涛
-
依托单位: